Patents by Inventor Takamasa Sugita
Takamasa Sugita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10894790Abstract: Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, analgesic resistance to opioid, migraine, movement disorder, depression, anxiety disorder and the like. Also provided is a production method of a compound represented by the formula (C), which contains (i) a step of reacting a compound represented by the formula (A) and a compound represented by the formula (B), and the like: (wherein R1 represents furyl, R4, R5 and R6 are the same or different and each represents lower alkyl or aryl, R2 represents pyridyl or tetrahydropyranyl, and X1 represents halogen).Type: GrantFiled: March 18, 2020Date of Patent: January 19, 2021Assignee: KYOWA KIRIN CO., LTDInventors: Takamasa Sugita, Arata Yanagisawa, Iwao Chujo, Masashi Taga, Akihiro Mimura, Atsushi Tada, Masashi Aoki
-
Publication number: 20200216438Abstract: Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, analgesic resistance to opioid, migraine, movement disorder, depression, anxiety disorder and the like. Also provided is a production method of a compound represented by the formula (C), which contains (i) a step of reacting a compound represented by the formula (A) and a compound represented by the formula (B), and the like: (wherein R1 represents furyl, R4, R5 and R6 are the same or different and each represents lower alkyl or aryl, R2 represents pyridyl or tetrahydropyranyl, and X1 represents halogen).Type: ApplicationFiled: March 18, 2020Publication date: July 9, 2020Inventors: Takamasa Sugita, Arata Yanagisawa, Iwao Chujo, Masashi Taga, Akihiro Mimura, Atsushi Tada, Masashi Aoki
-
Patent number: 10618894Abstract: Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, analgesic resistance to opioid, migraine, movement disorder, depression, anxiety disorder and the like. Also provided is a production method of a compound represented by the formula (C), which contains (i) a step of reacting a compound represented by the formula (A) and a compound represented by the formula (B), and the like: (wherein R1 represents furyl, R4, R5 and R6 are the same or different and each represents lower alkyl or aryl, R2 represents pyridyl or tetrahydropyranyl, and X1 represents halogen).Type: GrantFiled: January 14, 2019Date of Patent: April 14, 2020Assignee: KYOWA KIRIN CO., LTD.Inventors: Takamasa Sugita, Arata Yanagisawa, Iwao Chujo, Masashi Taga, Akihiro Mimura, Atsushi Tada, Masashi Aoki
-
Publication number: 20190144438Abstract: Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, analgesic resistance to opioid, migraine, movement disorder, depression, anxiety disorder and the like. Also provided is a production method of a compound represented by the formula (C), which contains (i) a step of reacting a compound represented by the formula (A) and a compound represented by the formula (B), and the like: (wherein R1 represents furyl, R4, R5 and R6 are the same or different and each represents lower alkyl or aryl, R2 represents pyridyl or tetrahydropyranyl, and X1 represents halogen).Type: ApplicationFiled: January 14, 2019Publication date: May 16, 2019Inventors: Takamasa Sugita, Arata Yanagisawa, Iwao Chujo, Masashi Taga, Akihiro Mimura, Atsushi Tada, Masashi Aoki
-
Patent number: 10214523Abstract: Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, analgesic resistance to opioid, migraine, movement disorder, depression, anxiety disorder and the like. Also provided is a production method of a compound represented by the formula (C), which contains (i) a step of reacting a compound represented by the formula (A) and a compound represented by the formula (B), and the like: (wherein R1 represents furyl, R4, R5 and R6 are the same or different and each represents lower alkyl or aryl, R2 represents pyridyl or tetrahydropyranyl, and X1 represents halogen).Type: GrantFiled: January 8, 2016Date of Patent: February 26, 2019Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Takamasa Sugita, Arata Yanagisawa, Iwao Chujo
-
Publication number: 20180002326Abstract: Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, analgesic resistance to opioid, migraine, movement disorder, depression, anxiety disorder and the like. Also provided is a production method of a compound represented by the formula (C), which contains (i) a step of reacting a compound represented by the formula (A) and a compound represented by the formula (B), and the like: (wherein R1 represents furyl, R4, R5 and R6 are the same or different and each represents lower alkyl or aryl, R2 represents pyridyl or tetrahydropyranyl, and X1 represents halogen).Type: ApplicationFiled: January 8, 2016Publication date: January 4, 2018Inventors: Takamasa Sugita, Arata Yanagisawa, Iwao Chujo, Masashi Taga, Akihiro Mimura, Atsushi Tada, Masashi Aoki
-
Patent number: 7605272Abstract: The present invention provides a type I insulin-like growth factor receptor (IGF-1R) inhibitor comprising, as an active ingredient, an indazole derivative represented by Formula (I): {wherein R1 represents —NR4R5 [wherein R4 represents a hydrogen atom or the like, R5 represents substituted or unsubstituted lower alkyl, —C(?O)R6 (wherein R6 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like), or the like], or the like, and R2 and R3 may be the same or different and each represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkoxy, or the like} or a pharmaceutically acceptable salt thereof, and the like.Type: GrantFiled: January 27, 2006Date of Patent: October 20, 2009Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Yutaka Kanda, Hiromi Ando, Keiko Kawashima, Takamasa Sugita, Masayo Suzuki, Hisashi Tagaya, Tomoyuki Nakazato, Yoshinori Yamashita, Takeshi Takahashi, Shinji Nara, Hiroaki Nakamura
-
Publication number: 20090054508Abstract: The present invention provides a type I insulin-like growth factor receptor (IGF-1R) inhibitor comprising, as an active ingredient, an indazole derivative represented by Formula (I): {wherein R1 represents —NR4R5 [wherein R4 represents a hydrogen atom or the like, R5 represents substituted or unsubstituted lower alkyl, —C(?O)R6 (wherein R6 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like), or the like], or the like, and R2 and R3 may be the same or different and each represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkoxy, or the like} or a pharmaceutically acceptable salt thereof, and the like.Type: ApplicationFiled: January 27, 2006Publication date: February 26, 2009Applicant: Kyowa Hakko Kogyo Co., Ltd.Inventors: Yutaka Kanda, Hiromi Ando, Keiko Kawashima, Takamasa Sugita, Masayo Suzuki, Hisashi Tagaya, Tomoyuki Nakazato, Yoshinori Yamashita, Takeshi Takahashi, Shinji Nara, Hiroaki Nakamura
-
Publication number: 20060058320Abstract: The present invention provides [1,2,4]triazolo[1,5-c]pyrimidine derivatives or pharmaceutically acceptable salts thereof which have adenosine A2A receptor antagonism and are useful for treating and/or preventing a disease induced by hyperactivity of an adenosine A2A receptor, the derivatives being represented by formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents a hydrogen atom, halogen, lower alkyl, lower alkanoyl, aroyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; R3 represents lower alkyl, lower cycloalkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; and Q represents a hydrogen atom or 3,4-dimethoxybenzyl).Type: ApplicationFiled: September 24, 2003Publication date: March 16, 2006Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kyoichiro Iida, Takamasa Sugita, Shizuo Shiozaki, Tomoyuki Kanda, Yoshihisa Kuwana, Junichi Shimada